The global autotransfusion devices market size was estimated to be USD 0.515 billion in 2023 and is anticipated to reach at USD 1.00 billion by 2034 with a CAGR of 6.28% during the forecast period 2024-2034. Rising number of surgical procedures, expanding aging population, increase in the prevalence of chronic conditions, growing demand for sophisticated blood management systems, heightened awareness of intraoperative & post-operative blood salvage, escalating collaborations and partnerships among industry leaders, surge in surgical procedures, a shortage of donated or allogenic blood, growing introduction of cutting-edge devices, and increase in approvals for advanced autotransfusion devices are some of the key factors boosting the market growth.
Increase in approvals for advanced autotransfusion devices is predicted to boost the market growth during the forecast period. Autotransfusion devices are extensively utilized for the collection and reinfusion of a patient's own blood. These systems play a significant role in cell salvage techniques, facilitating autologous blood transfusion to mitigate the risk of infections associated with allogeneic blood transfusions. Their applications span various surgical domains, including cardiovascular, orthopedic, neurological, obstetrics & gynecological, and other invasive procedures. Categorized based on usability, these systems include intraoperative systems, post-operative systems, and dual-mode systems. Consequently, continuous advancements in autotransfusion technology have resulted in the development of more effective and user-friendly devices. For instance, in March 2023, The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Haemonetics Corporation for the advanced software of the Cell Saver Elite+ Autotransfusion System. Known as Intelligent Control, this software update provides users with significant improvements aimed at streamlining operations, promoting increased efficiency, and enhancing the overall user experience.
By product, autotransfusion systems was the highest revenue-grossing segment in the global autotransfusion devices market in 2023 owing to the growing adoption of autotransfusion systems is attributed to their effectiveness in blood transfusion, coupled with advancing technologies aimed at achieving improved clinical outcomes and connectivity. Additionally, consumables & accessories is predicted to grow at the fastest CAGR during the forecast period owing to a heightened focus on the practice of intraoperative cell salvage in major invasive surgeries, and rising number of approvals from regulatory authorities. For instance, in September 2022, i-SEP has obtained CE-marking and commenced the marketing of its autotransfusion medical device, known as Same by i-SEP. This intraoperative autotransfusion technology is unique in its ability to preserve not only the patient's red blood cells but also platelets.
By application, cardiovascular surgeries was the highest revenue-grossing segment in the global autotransfusion devices market in 2023 owing to the increased use of these devices in cardiovascular surgical interventions, a rising frequency of cardiovascular procedures such as coronary artery bypass grafting (CABG), implantable cardioverter-defibrillator (ICD) & pacemaker implantations, heart transplantations, valve replacement surgeries, & other related procedures, and expanding collaborations among industry participants. For instance, in May 2022, Vetellus Specialities Ltd has entered into a five-year agreement with Euroset s.r.l, a manufacturer of autotransfusion devices. The agreement entails the provision of Vertullus PC technology coating by Vetellus to Eurosets for the application in devices used for cardiopulmonary bypass surgery and other purposes. Additionally, orthopedic surgeries is predicted to grow at the fastest CAGR during the forecast period owing to the increasing acceptance of post-operative cell salvage in orthopedic surgeries and growing incidence of orthopedic diseases.
By end-user, hospitals was the highest revenue-grossing segment in the global autotransfusion devices market in 2023 owing to the rising number of cardiovascular, obstetrics, & gynecological surgeries performed in hospitals and increasing number of advanced healthcare facilities. For instance, in June 2022, Haemonetics has inaugurated a Center of Excellence for manufacturing in Clinton, Pennsylvania, dedicated to the advancement of auto-transfusion systems. This purpose-built facility is anticipated to broaden the company's range of product offerings. Additionally, specialty clinics & others is predicted to grow at the fastest CAGR during the forecast period owing to the increasing utilization of intraoperative & post-operative cell salvage in specialty clinics and rising development of healthcare infrastructure.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing trend in utilizing autologous blood transfusion for significant cardiovascular and orthopedic surgeries, rising focus on incorporating intraoperative & postoperative cell salvage techniques, and surge in initiatives undertaken by prominent market players. For instance, in April 2023, San Diego Blood Bank has introduced Innovative Precision Blood Expansion, a groundbreaking method that matches blood recipients with donors of over 30 blood groups using 300 antigen markers. This advancement has the potential to decrease blood transfusion reactions, representing a transformative shift in the standard of care for patients. Additionally, Europe region is predicted to grow at fastest CAGR during the forecast period owing to the rising awareness of cell salvage technologies, increasing number of surgical procedures, advancing healthcare infrastructure, and a surge in the introduction of new devices. For instance, in May 2022, At the annual meeting of the Netherlands Society for Clinical Chemistry and Laboratory Medicine (NVKC) in Rotterdam, Vitestro, a medical robotics company, unveiled the most advanced autonomous blood drawing device globally. To ensure accurate and secure blood collection, this device combines robotic needle insertion with AI-based, ultrasound-guided 3D reconstruction.
Increase in approvals for advanced autotransfusion devices is predicted to boost the market growth during the forecast period. Autotransfusion devices are extensively utilized for the collection and reinfusion of a patient's own blood. These systems play a significant role in cell salvage techniques, facilitating autologous blood transfusion to mitigate the risk of infections associated with allogeneic blood transfusions. Their applications span various surgical domains, including cardiovascular, orthopedic, neurological, obstetrics & gynecological, and other invasive procedures. Categorized based on usability, these systems include intraoperative systems, post-operative systems, and dual-mode systems. Consequently, continuous advancements in autotransfusion technology have resulted in the development of more effective and user-friendly devices. For instance, in March 2023, The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Haemonetics Corporation for the advanced software of the Cell Saver Elite+ Autotransfusion System. Known as Intelligent Control, this software update provides users with significant improvements aimed at streamlining operations, promoting increased efficiency, and enhancing the overall user experience.
By product, autotransfusion systems was the highest revenue-grossing segment in the global autotransfusion devices market in 2023 owing to the growing adoption of autotransfusion systems is attributed to their effectiveness in blood transfusion, coupled with advancing technologies aimed at achieving improved clinical outcomes and connectivity. Additionally, consumables & accessories is predicted to grow at the fastest CAGR during the forecast period owing to a heightened focus on the practice of intraoperative cell salvage in major invasive surgeries, and rising number of approvals from regulatory authorities. For instance, in September 2022, i-SEP has obtained CE-marking and commenced the marketing of its autotransfusion medical device, known as Same by i-SEP. This intraoperative autotransfusion technology is unique in its ability to preserve not only the patient's red blood cells but also platelets.
By application, cardiovascular surgeries was the highest revenue-grossing segment in the global autotransfusion devices market in 2023 owing to the increased use of these devices in cardiovascular surgical interventions, a rising frequency of cardiovascular procedures such as coronary artery bypass grafting (CABG), implantable cardioverter-defibrillator (ICD) & pacemaker implantations, heart transplantations, valve replacement surgeries, & other related procedures, and expanding collaborations among industry participants. For instance, in May 2022, Vetellus Specialities Ltd has entered into a five-year agreement with Euroset s.r.l, a manufacturer of autotransfusion devices. The agreement entails the provision of Vertullus PC technology coating by Vetellus to Eurosets for the application in devices used for cardiopulmonary bypass surgery and other purposes. Additionally, orthopedic surgeries is predicted to grow at the fastest CAGR during the forecast period owing to the increasing acceptance of post-operative cell salvage in orthopedic surgeries and growing incidence of orthopedic diseases.
By end-user, hospitals was the highest revenue-grossing segment in the global autotransfusion devices market in 2023 owing to the rising number of cardiovascular, obstetrics, & gynecological surgeries performed in hospitals and increasing number of advanced healthcare facilities. For instance, in June 2022, Haemonetics has inaugurated a Center of Excellence for manufacturing in Clinton, Pennsylvania, dedicated to the advancement of auto-transfusion systems. This purpose-built facility is anticipated to broaden the company's range of product offerings. Additionally, specialty clinics & others is predicted to grow at the fastest CAGR during the forecast period owing to the increasing utilization of intraoperative & post-operative cell salvage in specialty clinics and rising development of healthcare infrastructure.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing trend in utilizing autologous blood transfusion for significant cardiovascular and orthopedic surgeries, rising focus on incorporating intraoperative & postoperative cell salvage techniques, and surge in initiatives undertaken by prominent market players. For instance, in April 2023, San Diego Blood Bank has introduced Innovative Precision Blood Expansion, a groundbreaking method that matches blood recipients with donors of over 30 blood groups using 300 antigen markers. This advancement has the potential to decrease blood transfusion reactions, representing a transformative shift in the standard of care for patients. Additionally, Europe region is predicted to grow at fastest CAGR during the forecast period owing to the rising awareness of cell salvage technologies, increasing number of surgical procedures, advancing healthcare infrastructure, and a surge in the introduction of new devices. For instance, in May 2022, At the annual meeting of the Netherlands Society for Clinical Chemistry and Laboratory Medicine (NVKC) in Rotterdam, Vitestro, a medical robotics company, unveiled the most advanced autonomous blood drawing device globally. To ensure accurate and secure blood collection, this device combines robotic needle insertion with AI-based, ultrasound-guided 3D reconstruction.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Autotransfusion Devices Market Report 2023 - 2034
Autotransfusion Devices Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Consumables & Accessories
- Autotransfusion Systems
- Intraoperative Autotransfusion Systems
- Dual-Mode Autotransfusion Systems
- Post-Operative Autotransfusion Systems
Autotransfusion Devices Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Neurological Surgeries
- Cardiovascular Surgeries
- Orthopedic Surgeries
- Obstetrics & Gynecological Surgeries
- Others
Autotransfusion Devices Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Ambulatory Surgical Centers
- Hospitals
- Specialty Clinics & Others
Autotransfusion Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Autotransfusion Devices Market: Product Estimates & Trend Analysis
8. Autotransfusion Devices Market: Application Estimates & Trend Analysis
9. Autotransfusion Devices Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Autotransfusion Devices Market
12. Europe Autotransfusion Devices Market
13. Asia Pacific Autotransfusion Devices Market
14. Latin America Autotransfusion Devices Market
15. MEA Autotransfusion Devices Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Gen World Medical Devices
- Advancis Surgical
- BD
- Fresenius SE & Co. KGaA
- SARSTEDT AG & Co. KG
- B. Braun SE
- LivaNova PLC
- Beijing Zhongke Zhengfang Technology Co. Ltd
- Teleflex Incorporated
- Haemonetics Corporation
- Medtronic
- Zimmer Biomet
- Braile Biomédica
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.52 Billion |
| Forecasted Market Value ( USD | $ 1 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
